Experts in mechanistic toxicity testing

Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing. We offer services in the following fields:

Genetic Toxicology

We have extensive experience and knowhow in the field of Genetic Toxicology. We often combine our unique ToxTracker assay with a range of extended protocols and additional assays to unravel the underlying mechanism of genotoxicity and predict the outcomes in the regulatory in vitro and in vivo genotoxicity assays.

Read more

Developmental Toxicology

By combining our expertise in stem cell technologies and reporter systems, we have generated ReproTracker, an in vitro assay that is able to visualise key processes in the early embryonic development. The assay can be applied to assess developmental toxicology in the early phases of drug development.

Read more

Mechanistic Toxicology

All assays that are developed at Toxys are aimed at understanding the mechanism underlying toxicity. We believe that this mechanistic understanding is key to translate the results from in vitro test systems to a relevance for humans. These mechanism-based test systems can be particularly useful in an Adverse Outcome Pathway (AOP) approach for both genotoxic and non-genotoxic carcinogens and in the development of an Integrated Approach to Testing and Assessment (IATA).

Read more

Toxys in 90 seconds

This video gives you a quick insight into what Toxys could do for you.

Read More

Happy Customers

We work together with a growing number of customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups. We offer unique in-house screening capabilities combined with the responsiveness and flexibility found only in smaller companies. Please read what some of our customers said about working together:

Belen Tornesi - Medicines for Malaria Venture
Senior Director of Pharmacology and Toxicology

“Generating human relevant developmental toxicity data at an early phase of drug development is crucial for safely progressing anti-malaria compounds to the clinic for pregnant women and WCBP who are the most affected by the disease after children. The ReproTracker assay is an ideal tool for this, and the team at Toxys has been instrumental for the interpretation of the data and to helps us develop a “anti-malaria compound library”. Amer’s willingness and scientific input was key to help solved some of the challenges that we face working with marketed compounds. The camaraderie developed between MMV and Toxys was crucial when we wrote scientific papers and presented data at international meetings.”

Yax Thakkar - RIFM
Genetic Toxicologist Scientist

“ToxTracker brings added value to the genotox testing strategy in the fragrances sector. Being able to distinguish between direct and indirect genotoxicity has instrumentally improved genotoxicity predictions and facilitates moving away from animal testing”.

Padmaja Yalamanchili - PTC Therapeutics
Vice President Preclinical Development

"The ToxTracker team helped us understand the mixed results we encountered in our standard in vitro genotoxicity assays. The mode-of-action information has proved to be very valuable in obtaining regulatory approval for progressing our compound into the clinic".

Maik Schuler - Pfizer
Research Fellow Toxicology

"The differentiation between aneugens and clastogens is important in the hazard assessment of our pharmaceutical compounds. ToxTracker ACE conveniently combines the relevant endpoints to be able to do this".

Paul Carmichael - Unilever
Senior Science Leader Toxicology

“We are very happy to work with Toxys to develop and implement ReproTracker for exposure-led in vitro developmental toxicity testing. Toxys have stood out as a developer and provider of data from innovative NAMs that underpin human-focused bioactivity point-of-departure determinations without pathology in animals. We experience a great synergy from our combined efforts to raise the bar in non-animal based next generation safety assessments”.

David Kirkland - Kirkland Consultancy
Consultant

“In regulatory assessment of carcinogenic or germ cell mutagenic risk, it is becoming increasingly important to understand mode of action, and not just rely on weight of negative evidence from in vivo genotoxicity studies to overrule positive in vitro genotoxicity results. To this end, there is increasing demand for integrated mechanism-based assays like ToxTracker as essential components in the development of safe and specific drugs or products.”

Erik Houthoff - Nouryon
Senior Toxicologist

"In our company we are striving to move away from animal testing as much as possible. While obtaining relevant mechanistic information for chemical safety assessment, the ToxTracker and ToxProfiler assays developed by Toxys also provide for an important contribution to the support of read-across approaches in regulatory submissions, and ultimately help in the reduction of animal testing".

Damian McHugh - Philip Morris Products
Manager cell & Genetic Toxicology

“As a modern safety laboratory requiring mechanistic insights into mammalian toxicology, we adopted ToxTracker and installed the assay in-house. The expertise, training and support provided by Toxys for the technology transfer were excellent resulting in a seamless set-up of the assay in our facilities. In addition, we have had terrific reactivity from Giel and his team with our questions.”

Jacky van Gompel
Genetic Toxicology

“A succesful genotoxicity screening strategy is always dependent on the availability of mechanism of action data, as this will provide a link towards risk assessment. The Toxtracker assay is able to provide this relevant information fast and reliable so that the medicinal chemist is able to drive his chemistry plan into the safe zone.”

Claudia Cusan - S&C BEST Srl
Consultant

“The expertise at Toxys is clear when you discuss results. The proactive team works hard to generate results within the timelines"

James Dawick - Innospec
Senior Toxicology and Risk Assessment Manager

“Innospec is a global specialty chemicals company focused on bringing novel and disruptive technologies to the markets we serve. As a company we are committed to replacing animal testing with suitable alternatives while ensuring that we can continue to innovate, develop and maintain new and safe products. To uphold these commitments we collaborate with excellent service providers like Toxys to generate data using modern state-of-art and scientifically robust safety testing. The ToxTracker and ToxProfiler assays have been very helpful in assessing the safety profile of numerous products from our portfolio which adds mode-of-action information that we can use to make biologically relevant decisions and enhance alternative approaches like read-across under regulations like EU REACH”.

Better in vitro dosing partners
Tulya Kavaklioglu

Create2Solve Funded Consortium Annual Progress Meeting

Toxys is one of the five partners in ‘Better in vitro dosing’ consortium, funded by ZonMw’s Create2Solve subsidy program that aims to create “More Knowledge with Fewer Animals”. Currently in Phase II of this project, ‘Better in vitro dosing’ consortium is working towards improving dosing...

toxtracker
Tulya Kavaklioglu

Toxys publication on OECD ring trial validation of ToxTracker

PRESS RELEASE Toxys reports positive results from the OECD ring trial validation of ToxTracker in a peer-reviewed article Oegstgeest, The Netherlands. April 9th, 2024 - Today Toxys announces the peer-reviewed publication of the positive results from an international interlaboratory validation of ToxTracker©. ToxTracker is an in vitro...

Two-scientists-pointing-at-an-imaging-result-of-neural-rosettes-scaled
Tulya Kavaklioglu

Toxys Awarded Phase 1 Project in CRACK IT Challenge

CRACK IT is a challenge-led competition that funds collaborations between industry, academics and SMEs to solve business and scientific Challenges which will deliver 3Rs benefits, either by improving business processes or developing a commercial product. Depending on the Challenge, contracts of up to £1M for...

Pereni K

Webinar: Potency ranking of PFAS using the ToxProfiler assay

On the 28th of November, we hosted a webinar entitled "Potency ranking of PFAS using the ToxProfiler assay". In this webinar, we shared a case study on the comparative analysis of different carbon chain length PFAS using ToxProfiler. Please click here to request the webinar from...

toxtracker
Pereni K

Webinar: Validation of ToxTracker for Regulatory Genetox Testing Strategies

On the 19th of September, we hosted a webinar entitled "Validation of ToxTracker for Regulatory Genetox Testing Strategies". During this webinar, we discussed the use of ToxTracker in genetic toxicology testing strategy and also presented findings of the inter-laboratory validation study approved by the OECD. Please...

Pereni K

Webinar: Applications of ToxProfiler for mechanistic toxicity profiling

On the 27th of June, we hosted a webinar entitled "Applications of ToxProfiler for mechanistic toxicity profiling". During this webinar, we introduces an exciting new extension of this assay, ToxProfiler MAX, and shared some case studies on ToxProfiler. Please click here to request the webinar from...

Pereni K

Join us at our ToxTracker hands-on training workshop!

[vc_row][vc_column][vc_column_text] Dates: 12 - 13 October 2023 Venue: Toxys B.V., De Limes 7, Oegstgeest, The Netherlands 2342 DH Join us for a hands-on training workshop on ToxTracker! ToxTracker is a unique genotoxicity assay that can reliably identify genotoxic compounds and can provide detailed insight into their mode-of-action. During the...